



Practitioner's Docket No. U 013888-7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent application  
of \_\_\_\_\_

Inventor(s) \_\_\_\_\_

for \_\_\_\_\_

Title of invention \_\_\_\_\_

OR

In re application of: JAMES W. DARROW, et al.

Serial No.: 10/083,245

Group No.: --

Filed: February 25, 2002

Examiner.: --

For: CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES  
AND PYRAZOLO [1,5-a]-1,3,5-TRIAZINES

Assistant Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
WITHIN THREE MONTHS OF FILING OR  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10\*

(When using Express Mail, the Express Mail label number is **mandatory**;  
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. 1.8(a)

37 C.F.R. 1.10\*

- ☒ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_ (mandatory)

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: March 25, 2002

Signature

JOHN RICHARDS

(type or print name of person certifying)

\* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

NOTE: 37 C.F.R. 1.98(b):

- (1) *Each U.S. patent listed in an information disclosure statement must be identified by inventor, patent number, and issue date.*
- (2) *Each U.S. patent application published listed in an information disclosure statement shall be identified by applicant, patent application publication number, and publication date.*
- (3) *Each U.S. application listed in an information disclosure statement must be identified by the inventor, application number, and filing date.*
- (4) *Each foreign patent or published foreign patent application listed in an information disclosure statement must be identified by the country or patent office which issued the patent or published the application, an appropriate document number, and the publication date indicated on the patent or published application.*
- (5) *Each publication listed in an information disclosure statement must be identified by publisher, author (if any), title, relevant pages of the publication, date, and place of publication.*

**WARNING:** *No extension of time can be had under 37 C.F.R. § 1.36 (a) or (b) for filing an IDS. 37 C.F.R. § 1.97(f).*

**NOTE:** *The "filing date of a national application" under 37 C.F.R. 1.97(b) has two possible meanings. Where the filing is a direct one to the United States Patent & Trademark office, the filing is defined in 37 C.F.R. 1.53(b) as "the date on which: (1) A specification containing a description pursuant to § 1.71 and at least one claim pursuant to § 1.75; and (2) any drawing required by § 1.81(a), are filed in the Patent and Trademark Office in the name of the actual inventor or inventors as required by § 1.41." 37 C.F.R. 1.97(b)(1). On the other hand, an international application that enters the national stage occurs when the applicant has filed the documents and fees required by 35 U.S.C. § 371(c) within the periods set forth in § 1.494 or § 1.495. 35 U.S.C. § 371(c) requires the filing of the following: (1) the national fee; (2) a copy of the international application, unless already sent by the International Bureau, and an English translation if filed in another language; (3) amendments under PCT Article 19, with a translation into English if made in another language; (4) an oath or declaration; and (5) a translation into English of any annexes to the international preliminary examination report, if such annexes were made in another language. 37 C.F.R. 1.97(b)(2).*

### **IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. 1.97(b).

**NOTE:** *"No certification or fee is due when the filing is made within the above time period. It is advisable to ensure that no Office action has been mailed if the disclosure statement is delayed until after three months from filing."*

**NOTE:** *"An information disclosure statement will be considered to have been filed on the day it was received in the Office, or on an earlier date of a mailing if accompanied by a properly executed certificate of mailing under 37 C.F.R. 1.8, or Express Mail certificate under 37 C.F.R. 1.10. An office action is mailed on the date indicated in the Office action." Notice of April 20, 1992 (1138 O.G. 37-41, 39).*

**NOTE:** *"The term 'national application' includes continuing applications (continuations, divisions, continuations-in-part) so three-months will be measured from the actual filing date of an application as opposed [sic] to the effective date of a continuing application." Notice of April 20, 1992 (1138 O.G. 37-41, 39).*

**NOTE:** "An action on the merits means an action which treats the patentability of the claims in an application, as opposed to only formal or procedural requirements. An action on the merits would, for example, contain a rejection or indication of allowability of a claim or claims rather than just a restriction requirements (37 C.F.R. 1.142) or just a requirement for additional fees to have a claim considered (37 C.F.R. 1.16(d)). Thus, if an application was filed on Jan. 1 and the first Office action on the merits was not mailed until six months later on July 1, the examiner would be required to consider any proper information disclosure statement filed prior to July 1." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

**WARNING:** "A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 37 C.F.R. 1.97 provides adequate recourse for the timely submission of prior art for consideration by the examiner." Notice of July 6, 1992 (1141 O.G. 63).

Reg. No. 31053

Tel. No.: (212) 708-1915

Customer No.: 00140

---

**SIGNATURE OF PRACTITIONER**

**JOHN RICHARDS**

*(type or print name of practitioner)*

---

P.O. Address

---

c/o Ladas & Parry  
26 West 61<sup>st</sup> Street  
New York, N.Y. 10023



TECH CENTER 1600/2900

APR 22 2002

RECEIVED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: JAMES W. **DARROW**, et al.

Serial No.: 10/083,245

Group No.: --

Filed: February 25, 2002

Examiner.: --

For: CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO [1,5-a]-1,3,5-TRIAZINES

Attorney Docket No.: U 013888-7


Assistant Commissioner for Patents  
Washington, D.C. 20231

Sirs:

INFORMATION DISCLOSURE STATEMENT

We draw the attention of the Examiner to the references listed on the attached Form PTO-1449. Copies of the references are not required, because they were already filed in a U.S. application from which an earlier filing date is claimed in this application.

Respectfully submitted,

  
\_\_\_\_\_  
JOHN RICHARDS  
LADAS & PARRY  
26 WEST 61<sup>ST</sup> STREET  
NEW YORK, NEW YORK 10023  
REG. NO. 31053 (212) 708-1915

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231

JOHN RICHARDS  
(Type or print name of person mailing paper)

Date: March 25, 2002

  
(Signature of person mailing paper)

FORM PTO-1449 U. S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

U 013888-7

10/083,245

APPLICANT

James W. DARROW, et al.

FILING DATE

GROUP

February 25, 2002

## REFERENCE DESIGNATION

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA	6 0 6 0 4 7 8	5/2000	Gilligan et al.	514	258	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO
AB	9 7 2 9 1 0 9	8/1997	WO			X	
AC	9 8 0 8 8 4 7	3/1998	WO			X	
AD	9 9 3 8 8 6 8	8/1999	WO			X	
AE	9 8 0 3 5 1 0	1/1998	WO			X	
AF	9 9 4 0 0 9 1	8/1999	WO			X	
AG	0 1 2 3 3 8 8	4/2001	WO			X	

## OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

AH	Britton, T.C., et al. "Structure-Activity Relationships of a Series of Benzothiophene-Derived NPY Y1 Antagonists: ... Chain" <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , Vol. 9, p. 475-480, (1999)	
	Hipskind, P.A., et al. "Potent and Selective 1,2,3-Trisubstituted Indole NPY Y-1 Antagonists" <i>J. Med. Chem.</i> , Vol. 40, p. 3712-3714, (1997)	
AJ	Murakami, Y., et al. "1,3-Disubstituted Benzazepines as Novel, Potent, Selective Neuropeptide Y Y1 Receptor Antagonists" <i>J. Med. Chem.</i> , Vol. 42, p. 2621-2632, (1999)	
	Tatemoto, K., et al. "Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide" <i>Nature</i> , Vol. 296, p. 659-660, (1982)	
AL	Wustrow, D.J., et al. "Pyrazolo[1,5-a]pyrimidine CRF-1 Receptor Antagonists" <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , Vol. 8, p. 2067-2070, (1998)	
	Zarrinmayeh, H., et al. "Synthesis and Evaluation of a Series of Novel 2-[(4-Chlorophenoxy)methyl]-benzimidazoles ... Antagonists", <i>J. Med. Chem.</i> , Vol. 41, p. 2709-2719, (1998)	
AM	Zarrinmayeh, H., et al. "Structure-activity Relationship of a Series of Diaminoalkyl Substituted Benzimidazole ... Antagonists" <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , Vol. 9, p. 647-652, (1999)	
	Zimmerman, D.M., et al. "Structure-activity Relationships of a Series of 1-Substituted-4-...Antagonists" <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , Vol. 8, p. 473-476, (1998)	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.